Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Large Cap Fund median (35 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 100 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | UTI - Large Cap Fund |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹102.56 |
| 12 Apr 2015 | ₹165.88 |
| 31 May 2016 | ₹154.85 |
| 19 Jul 2017 | ₹189.82 |
| 07 Sep 2018 | ₹221.51 |
| 27 Oct 2019 | ₹218.41 |
| 15 Dec 2020 | ₹266.72 |
| 03 Feb 2022 | ₹361.30 |
| 25 Mar 2023 | ₹336.17 |
| 12 May 2024 | ₹449.03 |
| 01 Jul 2025 | ₹523.05 |
| 20 Aug 2026 | ₹508.37 |
| Metric | UTI · Direct NAV ₹296.38 Very High risk ★★☆☆☆ | Category median Large Cap Fund · 35 funds |
|---|---|---|
| -1.96% | +0.75% | |
| +9.70% | +12.33% | |
| +8.85% | +11.21% | |
| +11.82% | +12.51% | |
| +12.67% | +13.22% | |
| +7.73% | — | |
| +13.61% | +14.61% | |
| +13.71% | +13.78% | |
| +13.50% | +13.95% | |
| Risk | ||
| 12.44% | 13.24% | |
| 0.26 | 0.43 | |
| 0.36 | 0.58 | |
| -34.65% | -35.14% | |
| Nifty 100 | — | |
| -0.21% | +2.33% | |
| 0.92 | 0.96 | |
| 92.9% | 103.3% | |
| 91.3% | 91.0% | |
| 1.07% | 1.07% | |
| ₹11,957Cr | ₹2,004Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 21% | 50% | |
| Karthikraj Lakshmanan | — | |
| 02 Jan 2013 | — | |
| 62 | — | |
| 50.1% | — | |
| 3.9% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.